Form 4: Upstream Bio, Inc. Executive Granted Stock Options

Allison Ambrose, General Counsel of Upstream Bio, Inc., was granted stock options for 25,000 shares on February 6, 2025, according to a Form 4 filing.

Summary

• Allison Ambrose, the General Counsel of Upstream Bio, Inc., was granted stock options to purchase 25,000 shares of common stock.
• The transaction occurred on February 6, 2025.
• The exercise price of the stock options is $8.53 per share.
• The options vest in 48 equal monthly installments starting February 6, 2025, contingent upon continued service.
• The expiration date for the options is February 5, 2035.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. It reflects a standard executive compensation practice, indicating confidence in the company's future.

Positives

• The grant of stock options aligns the General Counsel's interests with those of the shareholders.
• Vesting over four years encourages long-term commitment from the executive.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align their interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for executives in biotech companies of Upstream Bio's size and stage.
• The vesting schedule of 48 months is typical for such grants, aligning with industry norms for incentivizing long-term performance.
• Comparable companies like Arrakis Therapeutics and Dewpoint Therapeutics also utilize stock options as part of their executive compensation strategy.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive sign, aligning management's interests with their own.
• Employees may see this as a sign of the company's commitment to its leadership team.

Key Dates

Keywords

stock options, Form 4, Upstream Bio, Allison Ambrose, General Counsel, executive compensation, insider trading